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Background: Medication can control the symptoms of Parkinson’s disease (PD). Despite this, 
non-adherence with medication is prevalent in PD. Treatments for improving adherence with 
medication have been investigated in many chronic conditions, including PD. However, few 
researchers have evaluated their interventions qualitatively. We investigated the acceptability 
and potential mechanism of action of adherence therapy (AT) in PD patients and their spouse/
carers who received the intervention as part of a randomized controlled trial.
Methods: Sixteen participants (ten patients and six spouses/carers) who had recently com-
pleted the trial were purposely selected in order to cover a range of ages and disease severity. 
Semi-structured interviews were conducted in the participants’ homes. Data were transcribed 
and analyzed using a thematic approach. A second researcher, naïve to PD and AT, analyzed 
the data independently to limit bias.
Results: The trial showed that AT significantly improved both medication adherence and qual-
ity of life in people with PD. Specifically, patients who received AT reported improvements in 
mobility, activities of daily living, emotional wellbeing, cognition, communication, and body 
discomfort. General beliefs about medication also significantly improved in those who received 
AT compared with controls. In the current qualitative evaluation, a total of 175 codes were 
generated, which formed eleven subthemes. These could be grouped under three overarching 
themes, ie, perceptions prior to AT, positive effects of AT, and attributes of AT.
Conclusion: This randomized controlled trial is the first to investigate AT in PD. The accept-
ability and underlying mechanism of the intervention suggest a new multidirectional model 
of AT in PD which future research should seek to confirm. The findings provide a deeper 
understanding of AT and will allow clinicians to modify the delivery of the intervention by 
acknowledging various pathways to improved outcomes.
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Introduction
Anti-parkinsonian medication can control the symptoms of Parkinson’s disease (PD). 
Levodopa remains the most effective treatment, by replenishing dopaminergic tone 
in the nigrostriatal pathway. Monotherapy represents usual early phase management. 
However, more than half of PD patients take 2–4 anti-parkinsonian drugs 3–4 times 
daily. Advanced PD patients may be taking up to ten daily doses to manage fluctua-
tions. It is therefore not surprising that non-adherence is prevalent in PD.1
In a systematic review, we identified factors (eg, depression and regimen complex-
ity) associated with poor adherence in PD.2 Treatments for improving medication adher-
ence in chronic conditions have been widely investigated, with complex behaviorally 
targeted interventions reported to be most beneficial.3,4 However, few studies have 
focused on PD. Through a randomized controlled trial (RCT; ISRCTN07830951),5 
we recently reported the efficacy of a novel intervention, ie, adherence therapy (AT), 
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in PD.6 AT significantly improved adherence compared with 
routine care (odds ratio 8.2; 95% confidence interval [CI] 
2.8–24.3). Compared with routine care, AT also significantly 
improved quality of life (-9.0; 95% CI -12.2, -5.8).
Although the effectiveness of adherence-enhancing strat-
egies has been reported, few researchers have evaluated their 
interventions qualitatively. This is in terms of the underlying 
mechanism and the acceptability of the intervention from the 
perspective of patients. As a consequence, the mechanistic 
action of many adherence-enhancing strategies remains 
largely theoretical.
The aim of this qualitative explorative study was to 
investigate the experience of PD patients who received seven 
weekly sessions of AT as part of an RCT.6 Specifically, we 
were interested in patient acceptability, but we also aimed to 
explore potential mechanisms of action of AT in PD.
Materials and methods
Design and participants
Qualitative semi-structured interviews were undertaken 
with purposely selected participants (patients and spouse/
carers). Participants who had completed a program of AT 
were selected by the trial steering committee to capture a 
range of ages and disease severity.
Adherence therapy
AT is a cognitive-behavioral approach rooted in the observation 
that patient beliefs impact on adherence. The central theory is 
that when patients and professionals make choices collabora-
tively, patients are more likely to continue with those choices 
because they are personally owned and meaningful.7–9 Identi-
fication and amplification of the personally relevant benefits of 
treatment, modifying beliefs about medication, and exploring 
ambivalence toward taking medication are key components.
AT is delivered in five phases (Figure 1). Key skills 
include exchanging information (eg, explaining fluctuat-
ing drug concentrations through graphical representation), 
identifying inconsistencies between the patient’s thoughts 
and behaviors about medication, Socratic-style questioning, 
and working with resistance to discussing medication and 
treatment. Ethical approval was obtained from the Cambridge 
central research ethics committee (11/EE/0179).
Procedure and data generation
After completing seven AT sessions, DJD (who delivered 
AT as part of a PhD project) provided participants with an 
information sheet about the qualitative study. Interested 
participants were visited at home 1 week later to complete 
the consent procedures. Audio-recorded interviews were 
conducted by DJD in the participants’ homes to the point 
of saturation. Interviews were completed prior to RCT 
data analysis. Each interview explored the following broad 
topics: components of AT; communication style and therapy 
environment; participants’ perception of AT; and what par-
ticipants learned. The interview question prompts agreed by 
the trial steering committee are presented in Figure S1.
????????????????????
????????????????
?????????????????????????????????????????????????????????????????????????????????????
???????????
???????????????????????????????????????????????????????????????????????????????????????????????????????
????????????????????
Figure 1 Adherence therapy components and skills.
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Data analysis
Thematic analysis10 was used according to the phases 
described in the following sections.
initial code generation
Meaning from the data was used to generate codes that 
formed the basis of repeated patterns (subthemes). Codes 
were given definitions of their use/misuse and these were 
redefined to accommodate similar text segments.
searching for themes
The emphasis was on developing themes encompassing 
related codes. Codes were arranged into plausible subthemes. 
Relevant data extracts were then collated for each subtheme. 
This phase ended with a collection of candidate subthemes 
housing all codes and related extracts.
revising the themes
This involved two stages: in the first, DJD reviewed the col-
lated extracts from each subtheme to ensure they followed a 
logical pattern; in the second, a similar process was involved, 
but in relation to the data set. Specifically, DJD re-read the 
data set to ensure the generated subthemes were consistent 
with the original transcripts.
Defining and naming themes
Here broader themes were developed and defined. Short 
theme names were generated which portrayed enough infor-
mation to understand the content.
Quality assurance
A second qualitative researcher (RH), naïve to PD and AT, 
reviewed the transcripts independently. RH coded transcripts 
using the method described above. Despite generating 
different code names, the meaning of each code was con-
sistent between DJD and RH. Code names were discussed 
between the coders and the most appropriate was agreed.
Results
Baseline demographic and clinical characteristics are 
presented in Table 1. All patients were white Caucasians 
and retired (except for patient 10 who did not work due to 
PD). Seven patients were female and the mean (± standard 
deviation) age was 69.1±10.2 years. The mean time since 
diagnosis was 6.6±4.5 years. The Hoehn and Yahr score 
(a measure of disease severity) ranged from 0 (asymptomatic) 
to 4 (severe disability), with a median of 2.5 (interquartile 
range [IQR] 2). The median Montreal Cognitive Assessment 
Scale score was 26.5 (IQR 3), where #26/30 represents 
mild cognitive impairment. Using the Hospital Anxiety 
and Depression Scale, the median score was 6 (IQR 5) and 
5.5 (IQR 4) respectively (,8 represents no symptoms). 
Patients were taking at least one levodopa preparation. Six 
spouse/carers were interviewed. Interviews lasted a mean 
of 30 minutes. In total, 175 codes were generated. These 
formed eleven subthemes that were grouped under three 
main themes, ie, perceptions prior to AT, positive effects of 
AT, and attributes of AT (Table 2).
Perceptions prior to AT
Poor understanding of PD and medication
Most participants described having poor knowledge of 
PD prior to receiving AT. Most attributed this to a lack of 
previous explanation and/or opportunity to be informed in 
a meaningful way:
“The nature of the disease, nobody had ever explained that. 
I know the effect it has on me, but nobody explained it.” 
(Participant 1)
Table 1 Baseline characteristics of interview participants
Participant Age,  
years
Sex H&Y Duration of  
PD (years)
MoCA HADS LEDD  
(mg)
PD  
drugs
Daily  
dosesAnxiety Depression
1 56 Male 3 7 25 6 11 640 1 4
2 69 Male 2 7 28 6 3 740 2 7
3 72 Female 1 2 18 10 6 1,038 2 4
4 63 Male 3 4 27 5 2 1,758 4 12
5 71 Female 3 14 26 4 5 2,319 5 18
6 68 Female 1 6 30 4 3 247.5 2 4
7 72 Female 4 14 25 9 7 900 3 9
8 87 Female 0 2 24 3 1 187.5 1 3
9 80 Female 3 2 28 8 7 312.5 2 5
10 53 Female 1 8 27 13 10 480 3 13
Abbreviations: h&Y, hoehn and Yahr; MocA, Montreal cognitive Assessment scale; hADs, hospital Anxiety and Depression scale; leDD, levodopa equivalent daily 
doses; PD, Parkinson’s disease.
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“After diagnosis he wanted to be alone. He became 
depressed. He wanted me to help him end it. He became 
non-compliant and less confident, not just with medication.” 
(Spouse of participant 1)
Decreased support/increased isolation
Half of the patients described feeling isolated from people 
before AT. This feeling of isolation had a detrimental impact 
on daily life:
“Although you see the doctor, you’re still living it alone 
inside. Before this (AT), I felt isolated and lonely living with 
PD, even though my husband is here.” (Participant 5)
Additionally, people reported a lack of professional sup-
port and felt they were left alone to face their disease:
“We didn’t know where to turn or about what was coming. 
We felt we were the only people facing this.” (Spouse of 
participant 1)
Positive effects of AT
Participants spoke of having increased acceptance of PD 
and the need for medication. This appeared to be related to 
acquiring greater knowledge of PD. Participants described 
how self-awareness, confidence in daily life, support, self-
control, relationships with others, self-discipline, and an 
ability to function and cope were all improved after expe-
riencing AT.
increased acceptance
Several patients spoke of an increased acceptance of PD. This 
appeared to be associated with a developed understanding 
and acceptance of the indication for medication:
“Before I was in denial. I tried to ignore Parkinson’s and the 
pills. Now my relationship with medication has improved 
as I’m no longer scared.” (Participant 10)
Some participants described how their new perspective 
of life with PD helped them to re-evaluate their attitudes 
toward medication:
“I’ve got to take more control of the medication. Had you 
not come I would still be in the same situation, ambivalent 
to medicines. Talking about it has somehow changed me.” 
(Participant 5)
Alongside the increased acceptance of PD, some patients 
spoke of how they no longer felt the need to hide their condi-
tion from others:
Table 2 Themes generated by thematic analysis
Theme Subtheme PD patients 
(n)
Perceptions prior 
to adherence 
therapy
Poor knowledge and 
understanding of PD and 
medications
9
Low mood/confidence 5
Decreased support/isolation 5
Positive effects of 
adherence therapy
increased acceptance 5
increased self-awareness 5
Increased confidence 4
increased knowledge/
understanding of PD/
medications
10
increased control/self-
discipline
6
improved relationships 4
Attributes of 
adherence therapy
Therapy attributes
Flexibility, continuity, and 
timing
6
involved spouse 3
Face-to-face in home 
environment
10
Time to talk/openness 8
Therapist attributes
specialist knowledge 10
Understanding and 
interest
6
equal relationship 7
easy to understand 5
Abbreviation: PD, Parkinson’s disease.
The lack of understanding was not specific to PD. Simi-
larly, participants described how poor knowledge specific to 
medication use was also problematic:
“Before I would pop a pill and not understand why. Now 
I understand the peaks and troughs and why it’s essential 
to maintain a steady concentration to keep equilibrium.” 
(Participant 2)
Low confidence/mood
Half of the interviewees talked about their experiences of 
low mood, which they associated with PD. Low mood before 
commencing AT appeared to be related to lack of acceptance 
of PD, which impacted negatively on medication use in some 
participants:
“I was very low when we met. When I filled my medica-
tion wallet up I hated my pills and myself. I felt guilty for 
having it (PD), like I’d let my family down. I felt resentful 
towards the pills.” (Participant 10)
One spouse spoke of the devastating effect of PD on her 
husband’s mood and confidence:
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“I’m not afraid to say I’m disabled. Before, I wouldn’t even 
go outside. I’m better at explaining what I’ve got now.” 
(Participant 1)
increased self-awareness
Some participants described how “going off” was not thought 
to be related to suboptimal medication management. How-
ever, increased self-awareness of symptom control seemed 
to result from the enhanced understanding gained during 
the AT process:
“Before I was constantly eating to get some energy. Now 
I realize the sinking feeling is the Parkinson’s. I am going 
off. Having the medicines more strictly, I haven’t felt it as 
much.” (Participant 3)
Increased confidence
Participants spoke of how their experience of AT had 
improved their perceptions of symptom control, allowing 
them to feel more confident in their ability to manage life 
with PD:
“Once I was taking my meds as we agreed I felt a huge 
difference. The length of freezing was less. I felt more 
confident to go outside. I went for a coffee alone, it felt 
great. I haven’t done that for years.” (Participant 1)
Some patients described how their increased confidence 
resulted in greater social participation:
“It’s helped me socially. Before we met I wouldn’t tell 
anyone. Now I don’t mind talking to strangers about it 
(PD).” (Participant 2)
The spouse/carers of some patients reported how patients 
started to encourage medication adherence in others:
“He is now promoting what you’ve said, telling people how 
it’s helping. He remembers the conversations and is now 
talking to others.” (Spouse of participant 3)
increased knowledge of medication
Participants spoke of how improved knowledge enabled 
them to appreciate the relevance of medication, such as the 
importance of correct time interval dosing in relation to their 
own symptom fluctuations:
“I’ve learnt about peaks and troughs regarding the medica-
tion and why it’s important to take your medicine at certain 
times. I’ve learnt that in some respects I am governed by 
the clock.” (Participant 2)
Some patients appeared to link their increased knowl-
edge of PD medication to their improved self-awareness of 
symptoms:
“The peaks and troughs diagram was one of the most fasci-
nating explanations. It was very powerful for me. I realize 
now that I am dipping, falling, so it spurs me to take the 
medication correctly.” (Participant 3)
increased control/self-discipline
Several participants discussed how their experience of AT 
increased their self-control/discipline. Participants felt that 
they had become stricter with themselves regarding their 
medication use, describing a sense of increased power and 
ability to cope:
“The discussion made me strict with myself. I think it (AT) 
made me think about things, rather than you telling me what 
I must do.” (Participant 6)
Some described how problem-solving strategies, identi-
fied collaboratively through shared decision-making, helped 
them to develop a sense of control over medication use:
“Now I sometimes remember the pills before the alarm gets 
a chance to remind me.” (Participant 8)
improved relationships
Participants reported how AT helped improve their relation-
ships because of their increased sense of symptom control 
that they associated with feeling more confident:
“When I was non-compliant I convinced myself I couldn’t 
do anything. Then, for the first time in years, I cooked my 
own dinner and the wife’s too. She cried when she saw what 
I’d managed.” (Participant 1)
Some participants spoke of how family members, includ-
ing children, had noticed a difference in their ability to be 
more active and participatory:
“My granddaughter would come round and whereas I’d say 
sit there, we were going out to the park. I was doing more 
and she noticed.” (Participant 4)
Attributes of AT
All patients felt their success resulted from the flexibility 
of the topics discussed and the method in which they were 
introduced. The inclusion of spouse/carers was helpful, but 
for varied reasons. All participants described how the col-
laborative, participatory, and face-to-face nature of AT was 
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essential. The honesty and openness encouraged during the 
patient-professional interaction appeared to be paramount.
continuity and timing
Participants praised the continuity of sessions with the same 
therapist. Some patients thought the sessions could have been 
longer to facilitate greater in-depth discussion:
“They were too short. It hardly seemed to start and then 
it was gone. I like how we started where we left off.” 
(Participant 2)
involvement of spouse
The presence of a spouse/carer appeared helpful, par-
ticularly where they had an active role in management of 
medication:
“There was a lot for me as the carer because you opened my 
eyes to many things which I didn’t think were important.” 
(Spouse of participant 7)
in the home environment
Most participants discussed how the delivery of AT face-to-
face in their own homes was essential. All spoke of how they 
felt other forms of delivery would not be as effective:
“The way it (AT) was presented made a hell of an impact. 
You can’t judge someone and their reactions over the 
phone.” (Participant 2)
specialist knowledge
In addition to the AT program, interviewees described how 
the characteristics of the therapist were vitally important, 
such as the possession of specialist knowledge:
“Because you had an understanding of PD I was halfway 
there. There were so many issues I had that we spoke about. 
I’ve not been able to do that with others.” (Participant 10)
equal relationships
Several participants spoke of how honesty and a non- 
judgmental approach were key for encouraging open dialogue:
“It was welcoming not having to justify some of my 
actions. I felt I could say anything without you judging.” 
(Participant 2)
Several participants also discussed how building a rap-
port with the therapist was paramount for gaining the trust 
required to facilitate honest discussion:
“I felt comfortable telling you my fears. I was able to say the 
simplest things and you put me at ease.” (Participant 9)
Discussion
We explored the experiences of ten patients with PD and 
six spouses/carers who received a 7-week program of AT 
as part of a clinical trial.6 Thematic analysis generated three 
themes, ie, perceptions prior to AT, positive effects of AT, 
and attributes of AT.
Perceptions prior to AT
Most discussed their experiences prior to AT, referring to 
their poor understanding of PD and its treatments. Low 
mood/confidence and feeling isolated were also often 
reported. In many chronic conditions, people can become 
expert at symptom management.11 Medication adherence 
is therefore assumed in those with greater disease duration. 
Despite this, greater non-adherence is associated with longer 
disease duration in PD.2 Findings have shown that patients’ 
understanding of PD medication is often not sufficient to 
manage the disease, especially concerning the importance 
of dose timing.12 Given that our participants reported poor 
knowledge of treatment prior to AT, our findings suggest the 
expert patient concept should not be presumed in PD.
Low mood/depression appeared to be associated with a 
lack of acceptance of PD. This subsequently impacted on 
adherence. It is known that depression is associated with poor 
medication adherence in chronic conditions.13 Depression is 
the factor most strongly associated with non-adherence in 
PD.2 It is therefore not surprising that low mood was reported, 
especially as research suggests depression is prevalent in 40% 
of people with PD.14 Low confidence was evident in our par-
ticipants. As confidence can be associated with mood, this was 
not unexpected; low confidence in one’s ability to cope (low 
self-efficacy) is common in chronic conditions.13 Researchers 
have shown interventions aimed at enhancing self-efficacy 
may be beneficial for improving self-management behaviors.15 
This may include treatment adherence. Therefore, given that 
low confidence/mood are related and can affect medication 
adherence and general participation in life, this may explain 
why patients reported this as being significant prior to AT. 
Isolation and lack of support were also reported. This may sug-
gest that current service provision, such as access to PD nurse 
specialists, may not be wholly addressing patients’ needs.
Positive effects of AT
Participants reported how AT enabled them to appreciate 
the need for correct dose timing and to develop greater 
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self-awareness. Poor self-awareness of symptoms is docu-
mented in PD.16,17 The fact that this improved may suggest 
that discussing medication use in relation to problems 
identified by patients provides greater meaning because it is 
personally relevant. This may account, at least in part, for the 
improved adherence behaviors observed in our study.6
Greater self-discipline to manage medication was also 
described, suggesting that AT not only improves adher-
ence but also encourages patients to take control. Some 
described adapting problem-solving strategies, whilst others 
used their greater understanding to better plan drug dosing. 
This suggests that, after experiencing AT, patients may be 
more confident and competent to self-manage, which could 
improve adherence behaviors.
Several patients reported improved acceptance of PD and 
greater confidence in daily life. The linear mechanism of AT 
proposes that improving attitudes/beliefs about treatment, 
exchanging information, and assisting in problem-solving 
enhances medication adherence. These in turn improve clini-
cal outcomes.8,18 Because improving adherence/quality of life 
was our aim, it is unlikely that acceptance and confidence 
improved as a result of enhanced adherence. Furthermore, as 
acceptance and confidence to cope (self-efficacy) are important 
for optimizing quality of life, it is possible that our reported 
improvements may result from other mechanistic pathways.
For example, whilst the linear mechanism may explain 
findings in hypertension,19 improvements in acceptance 
and confidence in PD may suggest that quality of life can 
be enhanced without a requisite improvement in adher-
ence. As with the linear model, the pathways are likely to 
commence with identification of unique reasons for non-
adherence. This may include a lack of acceptance of PD and/
or underlying symptoms of anxiety/depression. However, 
unlike the linear model, where addressing such factors leads 
directly to improved adherence, addressing poor acceptance 
of PD and exploring factors for non-adherence may offer 
alternative pathways by first improving one’s confidence 
to cope with PD (ie, self-efficacy). This notion is consistent 
with reports of a positive correlation between self-efficacy 
and quality of life in other chronic conditions.20 Enhanced 
self-efficacy may impact positively on quality of life, which 
may lead to improved adherence behaviors. Therefore, 
whilst enhanced adherence may improve clinical outcomes, 
our findings indicate that AT is likely to be multidirectional 
in that people have unique pathways to improved outcomes 
(Figure 2). Although improving medication adherence was 
?????????????????
???????????????????????????????????????????????????
???????????????????????????????????????????????
?????????????????????????????????????????????????????????
????????????????????????????????????????????
??????????????????????????????????????????????????????????
?????????????????????????????????????????????????
???????????????????????????? ????????????????????????
Figure 2 Multidirectional model of adherence therapy in Parkinson’s disease. 
Abbreviation: PD, Parkinson’s disease.
Patient Preference and Adherence 2015:9submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
996
Daley et al
our objective, the therapeutic effect of AT may be holisti-
cally beneficial in PD.
Attributes of adherence therapy
The topics discussed during AT, the flexibility in delivery, 
and the timing of sessions were viewed favorably. This is 
consistent with findings in hypertension.19 Patients felt it was 
vital that the same therapist delivered AT to ensure continu-
ity. This should be recommended in future investigations. 
Gray et al showed that training mental health nurses to deliver 
AT resulted in significant improvements in medication 
adherence and symptoms in patients with schizophrenia.21 
Therefore, researchers should investigate whether training 
multiple nurse/therapists to provide AT as a service in PD 
leads to consistently positive outcomes.
Most of our study participants reported that the duration 
of AT was sufficient. Some wished for more sessions whereas 
others required fewer. In the RCT, AT was administered 
weekly for 7 consecutive weeks. Our findings suggest that 
AT may be more beneficial when delivered according to 
individual patient need. This approach mirrors findings 
showing that medication adherence is enhanced when suf-
ficient time is allocated for exploration of patient problems.22 
Therefore, it may be that some require “top-up” sessions, 
whereas others need a shorter duration to achieve the same 
therapeutic effect.
Patients viewed the inclusion of spouse/carers favorably. 
This is not surprising because spouse/carers can be crucial 
for helping patients to manage PD medication and often 
feel overwhelmed and unable to cope.23 As their inclusion 
seemed important, it is essential that this be acknowledged 
in future investigations.
All participants described how face-to-face AT set in 
the home environment was essential. Feeling encouraged to 
discuss concerns openly was viewed by many as contribut-
ing to the acceptability of AT. Whilst patients favored the 
flexibility of AT, the current findings suggest that deliver-
ing AT outside the home environment is not likely to be as 
effective. Home delivery of AT may offer several benefits. 
Firstly, problem-solving is likely to be more easily facili-
tated due to familiarity of environment, particularly where 
cognitive impairment is evident. Secondly, patients may 
feel more at ease to discuss topics that would normally 
make them anxious. Thirdly, unlike clinical environments, 
where patient-professional interactions are often directed by 
professionals, home delivery of AT may mean that patients 
perceive the power dynamic to shift. This may explain why 
many participants felt comfortable talking openly in a way 
they might not have done in the clinic. Alhalaiqa et al19 
showed a significant improvement in adherence and blood 
pressure in patients with hypertension who received AT either 
at home or in an outpatient department. Although patients in 
our RCT valued being at home, this finding proposes that AT 
may be effective when delivered in clinical settings. From 
an economic perspective, researchers should investigate 
the efficacy of AT in patients with PD when delivered via 
alternative means.
strengths and limitations
This evaluation of AT in PD has several strengths. Firstly, all 
participants were interviewed within 1 week of completing 
AT, so their recollection would have been maximized. Sec-
ondly, this study is the first to evaluate experiences of receiv-
ing an adherence-promoting intervention in PD. Finally, the 
use of a secondary qualitative researcher naïve to AT and PD 
provided quality assurance to the analysis process.
There are some limitations to this research. Firstly, only 
ten PD patients were interviewed. As our intention was 
to assess the acceptability of AT from the perspective of 
patients, the trial steering committee decided that a purposely 
selected sample would ensure we ascertained the views and 
experiences of a wider demographic. For this reason, despite 
the small sample, we feel it is unlikely that the views of the 
other RCT participants would differ substantially. Secondly, 
symptoms of anxiety/depression were assessed in our RCT, 
but at baseline only. However, self-efficacy was not assessed. 
As the interview findings suggest that enhancing self-efficacy 
and exploring symptoms of anxiety/depression may be ben-
eficial for improving confidence to cope with PD, it is essen-
tial that these be assessed as outcome measures in the future. 
Thirdly, as only some of our interviewees were cognitively 
impaired, it is possible that AT may be less beneficial in 
these patients. AT for cognitively impaired patients requires 
specific investigation. Finally, an independent interviewer 
would be desirable in future evaluations of AT.
Conclusion
We evaluated the acceptability of AT in PD. Three themes 
and eleven subthemes were identified and enhanced our 
understanding of AT. A new mechanism of action was 
proposed, which future research should seek to confirm. 
A recent priority setting partnership survey identified a need 
to better manage some of the symptoms of PD.24 However, 
many such symptoms are sensitive to levodopa.25–27 Improve-
ment in adherence is therefore essential. The findings of this 
qualitative evaluation provide a deeper understanding of the 
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potential underlying mechanism of AT. The proposed new 
model should allow researchers and clinicians to modify the 
delivery of AT by acknowledging the various pathways to 
improved outcomes.
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What did you find most helpful and least helpful?
When you started the programme, what were your expectations?
What happened that you did and didn’t like?
What did you think about session duration/environment and input of your carer?
What have you learnt? Has it changed the way you view your medication?
How could the therapy be improved, if at all?
Would you recommend the therapy?
Between the sessions did you think about what was talked about? How did it make you feel?
How have the sessions, if at all, made you think about your Parkinson’s disease?
Has the way you perceive your medication changed? How?
Figure S1 interview question prompts.
